A Plasma-derived Von Willebrand Factor/Factor VIII Concentrate (Wilate)
The FDA has approved a new plasma-derived von Willebrand factor/Factor VIII concentrate (Wilate –
Octapharma) for treatment of spontaneous and trauma-induced bleeding episodes in patients with von
Willebrand disease....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: A Plasma-derived Von Willebrand Factor/Factor VIII Concentrate (Wilate)
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1340
Article Code: 1340b
Date: June 14, 2010
Volume: 52
Pages: 46-47
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1340
Article Code: 1340b
Date: June 14, 2010
Volume: 52
Pages: 46-47
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)